Last reviewed · How we verify
Sibelium — Competitive Intelligence Brief
phase 2
flunarizine
Adenosine receptor A3, CAAX prenyl protease 2, 5-hydroxytryptamine receptor 1A
Pain
Small molecule
Live · refreshed every 30 min
Target snapshot
Sibelium (FLUNARIZINE). Flunarizine works by binding to the Sigma non-opioid intracellular receptor 1, which is involved in various cellular processes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sibelium TARGET | FLUNARIZINE | phase 2 | flunarizine | Adenosine receptor A3, CAAX prenyl protease 2, 5-hydroxytryptamine receptor 1A |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (flunarizine class)
- · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sibelium CI watch — RSS
- Sibelium CI watch — Atom
- Sibelium CI watch — JSON
- Sibelium alone — RSS
- Whole flunarizine class — RSS
Cite this brief
Drug Landscape (2026). Sibelium — Competitive Intelligence Brief. https://druglandscape.com/ci/flunarizine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing